Introduction: The objective of this study was to evaluate the prevalence and dissemination of carbapenem-resistant and metallo-beta-lactamase-producing Pseudomonas aeruginosa isolated from blood-stream samples (2000-2005) that were collected from patients admitted to the Institute of Pediatric Oncology, UNIFESP (IOP-GRAACC).
Methods And Results: Fifty-six P. aeruginosa samples were isolated from 49 patients. Thirty-two of these samples were classified as carbapenem-resistant using the disc diffusion method and were subjected to the PCR reaction in order to detect MBL genes. Eighteen of these 32 isolates showed the blaSPM-1 gene. Eight samples selected in different years over the study period presented the same genetic profile according to pulsed-field gel electrophoresis. The antimicrobial therapy was considered adequate for only 23.5% of the patients with bacteremia due to P. aeruginosa carrying the blaSPM-1 gene, and a high lethality rate of 70.6% was observed during the 30-day period after bacteremia and an inadequate initial antibiotic regimen.
Conclusions: We detected the presence of a clone of carbapenem-resistant P. aeruginosa carrying blaSPM-1 that persisted in blood culture samples over a six-year period at the institution, with high lethality, thus justifying rigorous epidemiological surveillance and a rearrangement of the antimicrobial therapy regimens at the institution.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/s0037-86822010000400007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Large, protracted, multi-species and multi-clonal spread of VIM-type metallo-β-lactamase-producing Enterobacterales in an Italian hospital.
J Hosp Infect
December 2024
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; Clinical Microbiology and Virology Unit, Careggi University Hospital, Florence, Italy. Electronic address:
Background: Carbapenem-resistant Enterobacterales, particularly those producing carbapenemase (CPE), pose a major threat to human health, being listed among critical-priority resistant pathogens by the World Health Organization.
Aim: To report on a large nosocomial spread of CPE of different species producing Verona integron-encoded metallo-β-lactamase (VIM)-type carbapenemases, and on the infection prevention and control measures that were adopted to combat the spread.
Methods: Conventional culture and molecular methods were used for detection and identification of VIM-positive CPE (VIM-CPE) causing infections or colonizing patients or present in environmental specimens.
Characterisation, management, and outcomes of New Delhi metallo-β-lactamase-producing Escherichia coli: A case series.
J Glob Antimicrob Resist
December 2024
Division of Infectious Diseases, Henry Ford Hospital, Detroit, MI, USA. Electronic address:
Objective: New Delhi metallo-β-lactamase (NDM)-producing carbapenem-resistant Enterobacterales (CRE) is a globally growing threat. We sought to describe the microbiology, management and outcomes of patients with this infection at our facility.
Methods: This is a descriptive case series of patients with NDM-producing Escherichia coli isolated from culture in Detroit between July 2021 and February 2023.
Aztreonam and avibactam combination therapy for metallo-β-lactamase-producing gram-negative bacteria: a comprehensive review.
Clin Microbiol Infect
November 2024
Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy; Laboratory Analysis Unit, University Hospital Policlinico-San Marco, Catania, Italy. Electronic address:
Background: Carbapenem-resistant gram-negative bacteria represent a challenging healthcare threat, accounting for metallo-β-lactamases (MBL) production increase across the world. MBL-producing Enterobacterales and Pseudomonas aeruginosa represent the main target for ultimate antibiotics combinations due to the difficulty to include carbapenems within the antimicrobial treatment.
Objectives: To provide a comprehensive review of the current knowledge about the aztreonam/avibactam (ATM-AVI) combination, which has emerged as a promising option for treating MBL-producing bacteria.
Insights into the Rising Threat of Carbapenem-Resistant Enterobacterales and Epidemic Infections in Eastern Europe: A Systematic Literature Review.
Antibiotics (Basel)
October 2024
Merck & Co., Inc., Rahway, NJ 07065, USA.
Background: Antimicrobial resistance is a major global public health challenge, particularly with the rise of carbapenem-resistant Enterobacterales (CRE) and (CRPA). This study aimed to describe the characteristics of CRE and CRPA infections in Eastern Europe, focusing on Bulgaria, Croatia, Czechia, Greece, Hungary, Poland, Romania, Serbia, Slovakia, and Slovenia.
Methods: Following MOOSE and PRISMA guidelines, a systematic literature review of articles published between 1 November 2017 and 1 November 2023 was conducted using the MEDLINE, Embase, Web of Science, CDSR, DARE, and CENTRAL databases.
Evaluation of point mutation carbapenemase-producing in Prapokklao Hospital, Thailand.
Microbiol Spectr
October 2024
Siriraj Center of Research Excellence in Allergy and Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Article Synopsis
- - This study focuses on the prevalence and genetic variations of carbapenemase-producing Enterobacteriaceae (CPE) in isolates from Prapokklao Hospital, Thailand, during 2016-2017, revealing that out of 122 carbapenem-resistant Enterobacteriaceae (CRE) isolates, a significant majority produced carbapenemase.
- - Various testing methods, such as the modified Hodge test and modified carbapenem inactivation method, confirmed that a high percentage of isolates were indeed producers of carbapenemase, with specific genetic mutations identified in the bla gene that denote different variants.
- - The findings emphasize the urgent need for rigorous infection control and active surveillance of antimicrobial resistance to manage the threat
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!